<DOC>
	<DOC>NCT00156182</DOC>
	<brief_summary>This study was designed to determine the long-term safety of asoprisnil 10 mg in women with one or more uterine fibroids after an initial 12 weeks in study M99-144.</brief_summary>
	<brief_title>A Long-Term Safety Study of Asoprisnil in the Treatment of Uterine Fibroids.</brief_title>
	<detailed_description>No medical therapy is currently available for the long-term treatment of uterine fibroids. The objective of this study is to determine the long-term safety of asoprisnil 10 mg daily for 6 months, after an initial 12 weeks in study M99-144, in women with one or more uterine fibroids, confirmed by ultrasound in study M99-144. The safety endpoints for this study will be based on ultrasound and endometrial biopsy results, adverse events, and any changes from baseline laboratory values and vital signs.</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Completed dosing and Day 84 procedures at sites in study M99144 No interruption of dosing Otherwise continued good health Any abnormal lab result the studydoctor considers significant History of severe reaction to or current use of hormone therapy History of alcohol or drug abuse</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Fibroid Uterus</keyword>
	<keyword>Leiomyoma</keyword>
	<keyword>Uterine Fibroids</keyword>
	<keyword>asoprisnil</keyword>
</DOC>